StratDeck

Two stocks in Healthcare

Danaher vs Gilead Sciences: profit, growth, debt and price compared

Danaher is stronger on 4 of 7 figures: profit margin, sales growth, debt and analysts' view. Gilead Sciences is stronger on 3: price for its expected profit, dividend and price trend.

Figures as of 18 November 2026SEC EDGARYahoo Finance
Explore Danaher's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Danaher and Gilead Sciences side by side
DanaherDHRGilead SciencesGILD
Net marginStronger: 16.9%−12.5%
Revenue growth, past yearStronger: +8.28%+6.83%
Debt to equityStronger: 51.8%202.5%
Forward P/E24.5×Stronger: 16.6×
Dividend yield0.71%Stronger: 1.92%
AnalystsStronger: Strong buy · 21Buy · 26
From its 200-day average+9.3%Stronger: +19.3%

Share price over the past year

  • Danaher+1.4%
  • Gilead Sciences+32.9%

18 Nov 202518 Nov 2026

Danaher or Gilead Sciences: which is stronger?

  • DHR

    Which is more profitable?

    Danaher keeps more of each sale as profit: 16.9% against −12.5%.

  • DHR

    Which is growing its sales faster?

    Danaher is growing its sales faster: +8.28% over the past year, against +6.83%.

  • DHR

    Which has borrowed less?

    Danaher has borrowed less: its debt is 51.8% of what its shareholders own, against 202.5% for Gilead Sciences.

  • GILD

    Which costs less for the profit it is expected to make?

    Gilead Sciences costs less for the profit it is expected to make: 16.6× its forward earnings, against 24.5×.

  • GILD

    Which pays more in dividends?

    Gilead Sciences pays more back in dividends for what a share costs: 1.92% a year, against 0.71%.

  • DHR

    Which do analysts rate higher?

    Analysts are warmer on Danaher: Strong buy, against Buy for Gilead Sciences.

  • GILD

    Which is in the stronger price trend?

    Gilead Sciences' price is in the stronger trend: 19.3% above its 200-day average, against 9.3% above.

What each company does

DHRDanaher

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Reports results on 27 January 2027

GILDGilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Reports results on 9 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.